Literature DB >> 3087560

Current clinical laboratory practice: investigation of plasma lipids--which tests and when?

W J Marshall, F C Ballantyne.   

Abstract

Clinical interest in the lipoproteins stems mainly from the association between serum cholesterol concentrations and coronary heart disease. Investigations of lipoproteins should be performed in patients with premature coronary heart disease, with a strong family history of coronary heart disease, or with certain cutaneous stigmata of hyperlipoproteinaemia and when fasting serum samples are seen to be lipaemic. Family studies should be performed in appropriate cases to identify relatives at increased risk of developing coronary heart disease. Patients with conditions known to cause secondary hyperlipoproteinaemia should be investigated if they fall into one of these categories but only after treatment of the underlying condition. Non-specialist laboratories should be able to measure total cholesterol and triglyceride concentrations and high density lipoprotein cholesterol concentrations. Lipoprotein electrophoresis has a limited role in such laboratories and is not necessary as a routine procedure. Specialist laboratories should in addition be able to measure individual lipoproteins and identify apolipoprotein E phenotypes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087560      PMCID: PMC1340714          DOI: 10.1136/bmj.292.6536.1652

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  20 in total

1.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

2.  Optimum serum cholesterol.

Authors: 
Journal:  Lancet       Date:  1982-10-09       Impact factor: 79.321

3.  The search for an optimum serum cholesterol.

Authors:  W B Kannel; T Gordon
Journal:  Lancet       Date:  1982-08-14       Impact factor: 79.321

4.  High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects.

Authors:  F C Ballantyne; R S Clark; H S Simpson; D Ballantyne
Journal:  Metabolism       Date:  1982-05       Impact factor: 8.694

5.  The need for better plasma cholesterol assays.

Authors:  P M Broughton; B M Buckley
Journal:  Ann Clin Biochem       Date:  1985-11       Impact factor: 2.057

6.  Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease.

Authors:  S B Hulley; R H Rosenman; R D Bawol; R J Brand
Journal:  N Engl J Med       Date:  1980-06-19       Impact factor: 91.245

7.  Response of plasma lipoproteins and acute phase proteins to myocardial infarction.

Authors:  F C Ballantyne; D A Melville; J P McKenna; B A Morrison; D Ballantyne
Journal:  Clin Chim Acta       Date:  1979-11-15       Impact factor: 3.786

8.  HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study.

Authors:  W P Castelli; J T Doyle; T Gordon; C G Hames; M C Hjortland; S B Hulley; A Kagan; W J Zukel
Journal:  Circulation       Date:  1977-05       Impact factor: 29.690

9.  The relationship between the cholesterol content and subfraction distribution of plasma high-density lipoproteins.

Authors:  J Shepherd; C J Packard; J M Stewart; B D Vallance; T D Lawrie; H G Morgan
Journal:  Clin Chim Acta       Date:  1980-02-14       Impact factor: 3.786

10.  Estimation of very-low-density lipoprotein cholesterol from data on triglyceride concentration in plasma.

Authors:  P W Wilson; R D Abbott; R J Garrison; W P Castelli
Journal:  Clin Chem       Date:  1981-12       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.